Study identification

PURI

https://redirect.ema.europa.eu/resource/1000000162

EU PAS number

EUPAS1000000162

Study ID

1000000162

Official title and acronym

DARWIN EU® - Chondrosarcoma: patient demographics, treatments, and survival in the period 2010-2023

DARWIN EU® study

Yes

Study countries

Finland
France
Netherlands
Spain
United Kingdom

Study description

This study is aimed to describe demographics, treatments, and overall survival of patients with incident chondrosarcoma, stratified by age, sex, study period, country/database, and, if available, by the AJCC/UICC TNM (Tumour, Nodes, Metastases) classification system of malignant tumors (AJCC/UICC TNM) stage categories and histological grade in 2010-2023.

The specific objectives of this study are:
1. To describe demographic characteristics (age and sex) of patients with chondrosarcoma at the time of diagnosis.
2. To describe chondrosarcoma treatment options (drug therapy, surgery, and radiation, when available).
3. To estimate the overall survival of newly diagnosed chondrosarcoma patients during the study period (2010-2023).

Study status

Ongoing
Research institution and networks

Institutions

Networks

Contact details

Talita Duarte-Salles

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
EMA
Study protocol
Initial protocol

DARWIN EU_D2.2.3_Protocol_P2-C1-003_v3.1_Chondrosarcoma.pdf

English (840.73 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable